Penumbra (PEN) to Release Quarterly Earnings on Wednesday

Penumbra (NYSE:PEN) is expected to announce its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect the company to announce earnings of $0.90 per share and revenue of $340.7730 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Penumbra Trading Down 0.4%

PEN stock opened at $226.41 on Tuesday. The business has a fifty day moving average price of $257.67 and a 200 day moving average price of $259.13. Penumbra has a fifty-two week low of $221.26 and a fifty-two week high of $310.00. The stock has a market capitalization of $8.83 billion, a price-to-earnings ratio of 60.21, a P/E/G ratio of 2.10 and a beta of 0.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 4.04.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on PEN shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Penumbra in a report on Wednesday, October 8th. UBS Group set a $335.00 price target on Penumbra and gave the company a “buy” rating in a report on Wednesday, July 30th. Evercore ISI dropped their price target on Penumbra from $300.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday, October 7th. Truist Financial dropped their price target on Penumbra from $310.00 to $300.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. Finally, Morgan Stanley increased their price objective on Penumbra from $260.00 to $266.00 and gave the company an “equal weight” rating in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $305.94.

Insider Transactions at Penumbra

In other news, Director Arani Bose sold 12,000 shares of the firm’s stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $250.65, for a total value of $3,007,800.00. Following the transaction, the director directly owned 558 shares in the company, valued at $139,862.70. This trade represents a 95.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Maggie Yuen sold 2,000 shares of the firm’s stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $250.00, for a total value of $500,000.00. Following the completion of the transaction, the chief financial officer owned 12,943 shares in the company, valued at $3,235,750. This represents a 13.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 64,460 shares of company stock worth $16,322,614. Corporate insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PEN. State of Wyoming bought a new position in shares of Penumbra in the 2nd quarter worth $64,000. EverSource Wealth Advisors LLC lifted its holdings in Penumbra by 209.1% during the second quarter. EverSource Wealth Advisors LLC now owns 272 shares of the company’s stock worth $70,000 after acquiring an additional 184 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in Penumbra by 28.3% during the second quarter. Lazard Asset Management LLC now owns 902 shares of the company’s stock worth $231,000 after acquiring an additional 199 shares in the last quarter. Two Sigma Securities LLC lifted its holdings in Penumbra by 36.2% during the second quarter. Two Sigma Securities LLC now owns 1,625 shares of the company’s stock worth $417,000 after acquiring an additional 432 shares in the last quarter. Finally, Captrust Financial Advisors lifted its holdings in Penumbra by 33.4% during the second quarter. Captrust Financial Advisors now owns 1,986 shares of the company’s stock worth $510,000 after acquiring an additional 497 shares in the last quarter. 88.88% of the stock is currently owned by institutional investors.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.